Research Confirms that vCJD Prions Can be Removed From Blood; New Pall Technology Reduces Risk of Human-to-Human 'Mad Cow' Transmission by Transfusion

Business Wire, Oct 25, 2004

The new filter is an integral component of the Pall Life Sciences technology platform, which provides several products to enhance the safety of the world's blood supply. Pall is the global leader in leukocyte reduction technology and also provides the enhanced Bacterial Detection System to test platelets for contamination prior to transfusion. The Company also provides products to remove infectious agents including viruses, bacteria and prions from biologicals used for the manufacture of medicines.

About Pall Corporation

Pall Corporation is the leader in the rapidly growing fields of filtration, separations and purification. Pall's business is organized around two broad markets: Life Sciences and Industrial. The Company provides leading-edge products to meet the demanding needs of customers in biotechnology, pharmaceuticals, transfusion medicine, semiconductors, municipal drinking water, aerospace and broad industrial markets. Total revenues are $1.77 billion. The Company headquarters are in East Hills, New York with operations in about 40 countries. Visit Pall at www.pall.com.

This release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current Company expectations and are subject to risk and uncertainties, which could cause actual results to differ materially. Such risks and uncertainties include, but are not limited to: fluctuations in foreign currency exchange rates; regulatory approval and market acceptance of new technologies; changes in product mix and product pricing and in interest rates and cost of raw materials; the Company's success in enforcing its patents and protecting its proprietary products and manufacturing techniques and its ability to achieve the savings anticipated from its cost reduction initiatives; global and regional economic conditions and legislative, regulatory and political developments; and domestic and international competition in the Company's global markets. Additional information regarding these and other factors is available on the Web at www.pall.com and is included in the Company's reports filed with the U.S. Securities and Exchange Commission. Copies of such reports can be obtained, without charge, at www.sec.gov.

Editor's notes:

--Additional information and photos are available on www.pall.com/pressroom

--Samuel O. Coker, Ph.D. is presenting the results of the two studies on Monday October 25th at 2:45 p.m., Baltimore Convention Center, Room 349/350 in an AABB scientific platform. He will repeat the highlights of these results in an evening symposium "TSEs--Measures to Reduce the Global Risk to the Blood Supply: Experts Present their Views" at 7:00 p.m. in the Grand Ballroom, Marriott Waterfront Hotel, Baltimore.

--Media are invited to attend both events and interviews are available upon request. Media can also listen to the symposium by telephone. Call Susan Youdovin for reservations 973.746.8183 or 973.715.6570